References
- Hirohata S, Kikuchi H. Behget's disease. Arthritis Res Ther. 2003;5:139–46.
- Hirohata S. Potential new therapeutic options for involvement of central nervous system in Behget's disease (Neuro-Behget's syndrome). Curr Rheumatol Rev. 2007;3:297–303.
- Al-Araji A, Kidd DP. Neuro-Behçet's disease: epidemiology, clinical characteristics, and management. Lancet. 2009;8:192–204.
- Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet's syndrome. Clin Immunol Immunopathol. 1997;82: 12–7.
- Hirohata S, Suda H, Hashimoto T. Low-dose weekly metho-trexate for progressive neuropsychiatric manifestations in Behget's disease. J Neurol Sci. 1998;159:181–5.
- Ribi C, Sztajzel R, Delavelle J, Chizzofini C. Efficacy of TNF-a blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry. 2005;76:1733–5.
- Pipitone N. Infliximab for the treatment of Neuro-Behcet's dis-ease: a case series and review of the literature. Arthritis Rheum. 2008;58:285–90.
- Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in pro-gressive Neuro-Behcet's syndrome. J Neurol Sci. 2008;272:99–105.
- Akman-Demir G, Tiiztin E, köz S, YeOlot N, Yentiir SP, Kik-tiincti M, Mutlu M, Saruhan-Direskeneli G. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine. 2008;44: 373–6.
- Haghighi AB, Ittehadi H, Nikseresht AR, Rahmati J, Poorjahromi SG, Pourabbas B, Nazarinia MA, Habibagahi Z, Fattahi MJ, Ghaderi A. CSF levels of cytokines in neuro-Behçet's disease. Clin Neurol Neurosurg. 2009;111:507–10.
- Saruhan-Direskeneli G, Yenttir SP, Akman-Demir G, Iik N, Serdaroglu P. Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145:127–34.
- Hirohata S. Histopathology of central nervous system lesions in Behçet's disease. J Neurol Sci. 2008;267:41–7.